We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Tests Can Reveal Brain Damage Caused by Neurosurgery

By LabMedica International staff writers
Posted on 01 Jun 2023

Currently, magnetic resonance imaging (MRI) is the go-to method following brain surgery to determine potential damage to the patient's brain. More...

MRI is useful for detecting signs of hemorrhage and areas of the brain affected by ischemia due to poor blood flow. However, its limitations lie in providing an accurate estimate of the degree of cell injury. Now, it may be possible to assess damage to the brains of patients operated on for brain tumors by measuring biomarkers in the pre-and post-surgery. The increase in these markers is correlated with the damage caused by inadequate blood flow, according to the findings of a new study.

Researchers at The University of Gothenburg (Gothenburg, Sweden) investigated the biomarkers, namely neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and tau protein, in patients operated on for brain tumors. The role of these biomarkers in neurological diseases, especially Alzheimer's and other dementias, and in patients with traumatic brain injuries, has been well researched. NfL is indicative of nerve cell fiber damage, GFAP signifies injury to the brain's supporting cells, while tau points to nerve cell impairment.

In the present study, 34 adult patients diagnosed with glioma, a common brain tumor type, were included. The biomarkers' concentration was first measured a day before surgery, then successively on days one, three, five, and ten post-operation. The study found that the blood markers' levels were in sync with both the degree of injury from oxygen deprivation during surgery and the severity of the neurological deficit experienced by the patients. This means that the practice of measuring blood biomarkers could potentially pave the way for a novel approach to assess neurosurgery-induced injuries, consequently facilitating the comparison of different surgical methodologies.

“It’s also conceivable that high levels of these markers might be signs of damage that could cause brain fatigue or other cognitive problems for the patients in the somewhat longer term,” said Isak Michaëlsson, a doctoral student at the University of Gothenburg and resident in neurosurgery at Sahlgrenska University Hospital. “If so, the markers could be used to identify patients at an early stage so that they get the right kind of rehabilitation.”

Related Links:
The University of Gothenburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.